Search
Feed aggregator
Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data
Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data 7/10/2024
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists 7/10/2024
Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors
Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors 7/10/2024
Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia
Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia 7/10/2024
Why Is Antimicrobial Resistance Not Getting Much Attention from Biopharma?
Why Is Antimicrobial Resistance Not Getting Much Attention from Biopharma? 7/10/2024
Opinion: To Realize AI’s Benefits, Don’t Lose Sight of Fundamentals
Opinion: To Realize AI’s Benefits, Don’t Lose Sight of Fundamentals 7/10/2024
Adcomm Votes Unanimously for Lilly’s Alzheimer’s Treatment Donanemab
Adcomm Votes Unanimously for Lilly’s Alzheimer’s Treatment Donanemab 6/10/2024
Moderna’s COVID-Flu Combo Shot Beats Separate Vaccines in Phase III Study
Moderna’s COVID-Flu Combo Shot Beats Separate Vaccines in Phase III Study 6/10/2024
Alumis Files for IPO to Fund Phase III Trials of Potential Rival Drug to BMS’ Sotyktu
Alumis Files for IPO to Fund Phase III Trials of Potential Rival Drug to BMS’ Sotyktu 6/10/2024
Pfizer’s Paxlovid Ineffective Against Long COVID Using 15-Day Regimen: Study
Pfizer’s Paxlovid Ineffective Against Long COVID Using 15-Day Regimen: Study 6/10/2024
Skye Nixes Eye Disease Drug After Phase II Failure, Focuses on Metabolic Program
Skye Nixes Eye Disease Drug After Phase II Failure, Focuses on Metabolic Program 6/10/2024
GSK’s RSV Shot Wins Expanded FDA Approval for At-Risk Adults Aged 50 to 59
GSK’s RSV Shot Wins Expanded FDA Approval for At-Risk Adults Aged 50 to 59 6/10/2024
Lilly’s Tirzepatide Improves Liver Fibrosis in Phase II MASH Trial
Lilly’s Tirzepatide Improves Liver Fibrosis in Phase II MASH Trial 6/10/2024
Amyloid Remains a Key Target in Next-Generation Alzheimer’s Treatments
Amyloid Remains a Key Target in Next-Generation Alzheimer’s Treatments 6/10/2024
Measuring Muscle Loss in the ‘Wild West’ of Weight Loss Drugs
Measuring Muscle Loss in the ‘Wild West’ of Weight Loss Drugs 6/10/2024
Psychedelic Therapies Could Soon Break Through Against Addiction
Psychedelic Therapies Could Soon Break Through Against Addiction 6/10/2024
Opinion: GenAI Is Not a One-Size-Fits-All Solution for Regulatory Operations
Opinion: GenAI Is Not a One-Size-Fits-All Solution for Regulatory Operations 6/10/2024
Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine
Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine 5/10/2024
Cell and Gene Therapies Still Have Long Way to Go in Fulfilling Promise
Cell and Gene Therapies Still Have Long Way to Go in Fulfilling Promise 5/10/2024
Five Deaths in Prostate Cancer Trial Send MacroGenics’ Stock Plummeting
Five Deaths in Prostate Cancer Trial Send MacroGenics’ Stock Plummeting 5/10/2024
World Pharma News
- Next-generation microbiome medicine may revolutionize the treatment of Parkinson's and similar disorders
- A cellular protein, FGD3, boosts breast cancer chemotherapy, immunotherapy
- Common gout drug may reduce risk of heart attack and stroke
- New nasal vaccine has potential to transform respiratory disease prevention
- MIT research finds particles that enhance mRNA delivery could reduce vaccine dosage and costs